Literature DB >> 18097887

Associations of cigarette smoking with viral immune and cognitive function in human immunodeficiency virus-seropositive women.

Valerie Wojna1, Lizbeth Robles, Richard L Skolasky, Raul Mayo, Ola Selnes, Tania de la Torre, Elizabeth Maldonado, Avindra Nath, Loyda M Meléndez, Jose Lasalde-Dominicci.   

Abstract

Cigarette smoking alters the immune system and may improve cognitive deficits in neuropsychiatric disorders. Smoking prevalence is high in human immunodeficiency virus (HIV)-infected patients; however, its effect on HIV-associated cognitive impairment remains unknown in the era of antiretroviral treatment. The authors examined associations of smoking with viral immune profile and cognitive function in a cohort of HIV-seropositive women. This observational cross-sectional study included 56 women (36 HIV-seropositive and 20 HIV-seronegative) surveyed with a tobacco questionnaire: the Fagerström Test for Nicotine Dependency. Viral immune status was obtained 6 to 12 months before questioned. Neurocognitive testing (NP) assessed verbal memory, frontal/executive function, psychomotor speed, and motor speed. A reference group of HIV-seronegative women was used to calculate standardized z-scores. Cognitive impairment was classified using a modified American Academy of Neurology criteria, adding an asymptomatic group based on NP tests. Statistics included parametric and nonparametric tests. HIV-seropositive women were more likely to report a history of smoking (P = 0.028). Among them, current smoking correlated with higher plasma viral load (P = 0.048), and history of smoking correlated with lower CD4 cell count (P = 0.027). The authors observed no associations between cognitive impairment and either current or past history of smoking and no differences in neurocognitive domain scores between HIV-seropositive and -seronegative women or between those with and without a history of smoking. However, restricting analysis to HIV-seropositives showed a significant better performance on the frontal/executive domain in those with history of smoking. In summary, history of smoking correlated with better frontal/executive cognitive domain performance in HIV-seropositive women and with worse viral immune profile.

Entities:  

Mesh:

Year:  2007        PMID: 18097887      PMCID: PMC4962997          DOI: 10.1080/13550280701620747

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  51 in total

1.  Clinical confirmation of the American Academy of Neurology algorithm for HIV-1-associated cognitive/motor disorder. The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders.

Authors: 
Journal:  Neurology       Date:  1996-11       Impact factor: 9.910

2.  Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy.

Authors:  K E Poundstone; R E Chaisson; R D Moore
Journal:  AIDS       Date:  2001-06-15       Impact factor: 4.177

3.  Cigarette smoking: a modifier of human immunodeficiency virus type 1 infection?

Authors:  D N Burns; A Kramer; F Yellin; D Fuchs; H Wachter; R A DiGioia; W C Sanchez; R J Grossman; F M Gordin; R J Biggar
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991

4.  Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms.

Authors:  Kristi A Sacco; Angelo Termine; Aisha Seyal; Melissa M Dudas; Jennifer C Vessicchio; Suchitra Krishnan-Sarin; Peter I Jatlow; Bruce E Wexler; Tony P George
Journal:  Arch Gen Psychiatry       Date:  2005-06

5.  Female sex and oral contraceptive use accelerate nicotine metabolism.

Authors:  Neal L Benowitz; Christina N Lessov-Schlaggar; Gary E Swan; Peyton Jacob
Journal:  Clin Pharmacol Ther       Date:  2006-05       Impact factor: 6.875

6.  Cigarette smoking and the desire to quit among individuals living with HIV.

Authors:  Edward M Mamary; Darlene Bahrs; Sharon Martinez
Journal:  AIDS Patient Care STDS       Date:  2002-01       Impact factor: 5.078

7.  A menopause-specific quality of life questionnaire: development and psychometric properties.

Authors:  J R Hilditch; J Lewis; A Peter; B van Maris; A Ross; E Franssen; G H Guyatt; P G Norton; E Dunn
Journal:  Maturitas       Date:  1996-07       Impact factor: 4.342

8.  Smoking and malignancy in schizophrenia.

Authors:  E Masterson; B O'Shea
Journal:  Br J Psychiatry       Date:  1984-10       Impact factor: 9.319

9.  T cell subsets in healthy black smokers and nonsmokers. Evidence for ethnic group as an important response modifier.

Authors:  D J Tollerud; L M Brown; W A Blattner; D L Mann; L Pankiw-Trost; R N Hoover
Journal:  Am Rev Respir Dis       Date:  1991-09

10.  HIV infection, cigarette smoking and CD4+ T-lymphocyte counts: preliminary results from the San Francisco Men's Health Study.

Authors:  R A Royce; W Winkelstein
Journal:  AIDS       Date:  1990-04       Impact factor: 4.177

View more
  32 in total

1.  Cigarette Smoking and Antiretroviral Therapy (ART) Adherence in a Sample of Heavy Drinking HIV-Infected Men Who Have Sex with Men (MSM).

Authors:  Patricia A Cioe; Kristi E Gamarel; David W Pantalone; Peter M Monti; Kenneth H Mayer; Christopher W Kahler
Journal:  AIDS Behav       Date:  2017-07

Review 2.  Modulatory Effects of Nicotine on neuroHIV/neuroAIDS.

Authors:  Haijun Han; Zhongli Yang; Sulie L Chang; Ming D Li
Journal:  J Neuroimmune Pharmacol       Date:  2018-09-13       Impact factor: 4.147

Review 3.  Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD.

Authors:  R N van Zyl Smit; M Pai; W W Yew; C C Leung; A Zumla; E D Bateman; K Dheda
Journal:  Eur Respir J       Date:  2010-01       Impact factor: 16.671

4.  Crack cocaine use impairs anterior cingulate and prefrontal cortex function in women with HIV infection.

Authors:  Vanessa J Meyer; Deborah M Little; Daniel A Fitzgerald; Erin E Sundermann; Leah H Rubin; Eileen M Martin; Kathleen M Weber; Mardge H Cohen; Pauline M Maki
Journal:  J Neurovirol       Date:  2014-04-24       Impact factor: 2.643

Review 5.  The convergence of the global smoking, COPD, tuberculosis, HIV, and respiratory infection epidemics.

Authors:  Richard N van Zyl-Smit; Laurence Brunet; Madhukar Pai; Wing-Wai Yew
Journal:  Infect Dis Clin North Am       Date:  2010-09       Impact factor: 5.982

6.  Translational spatial task and its relationship to HIV-associated neurocognitive disorders and apolipoprotein E in HIV-seropositive women.

Authors:  Diana Morales; Summer F Acevedo; Richard L Skolasky; Rosa Hechavarria; Sharon Santiago; Tania De La Torre; Elizabeth Maldonado; Valerie Wojna
Journal:  J Neurovirol       Date:  2012-09-13       Impact factor: 2.643

7.  Mechanisms of Cognitive Aging in the HIV-Positive Adult.

Authors:  Asante Kamkwalala; Paul Newhouse
Journal:  Curr Behav Neurosci Rep       Date:  2017-07-19

8.  Association of midlife smoking status with change in processing speed and mental flexibility among HIV-seropositive and HIV-seronegative older men: the Multicenter AIDS Cohort Study.

Authors:  Wajiha Z Akhtar-Khaleel; Robert L Cook; Steve Shoptaw; Eric N Miller; Ned Sacktor; Pamela J Surkan; Jim Becker; Linda A Teplin; Rebecca J Beyth; Catherine Price; Michael Plankey
Journal:  J Neurovirol       Date:  2016-11-26       Impact factor: 2.643

9.  Smoking and HIV-related health issues among older HIV-positive gay, bisexual, and other men who have sex with men.

Authors:  Danielle C Ompad; Molly Kingdon; Sandra Kupprat; Sophia N Halkitis; Erik David Storholm; Perry N Halkitis
Journal:  Behav Med       Date:  2014       Impact factor: 3.104

10.  Plasma and mucosal HIV viral loads are associated with genital tract inflammation in HIV-infected women.

Authors:  Betsy C Herold; Marla J Keller; Qiuhu Shi; Donald R Hoover; Colleen A Carpenter; Ashley Huber; Urvi M Parikh; Kathy J Agnew; Howard Minkoff; Christine Colie; Marek J Nowicki; Gypsyamber DʼSouza; D Heather Watts; Kathryn Anastos
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.